S-1 in combination with docetaxel and oxaliplatin in patients with advanced gastro-esophageal adenocarcinoma: two parallel phase 1/2a studies. (2nd January 2017)

• Record Type: Journal Article
• Authors: Pfeiffer, Per; Qvortrup, Camilla; Krogh, Merete; Schoennemann, Katrine; Vestermark, Lene W.; Jensen, Helle A.; Bjerregaard, Jon K.
• Is Part Of: Acta oncologica. Volume 56:Number 1(2017)
• Page Start: 46
• Page End: 51
• Publication Date: 2017-01-02
• Subjects: Oncology -- Periodicals; Cancer -- Treatment -- Periodicals; 616.992
• DOI: 10.1080/0284186X.2016.1257865
• Languages: English
• ISSNs: 0284-186X

Abstract

Abstract: Background: Docetaxel in combination with cisplatin and 5-fluorouracil (5-FU) is one of several standard chemotherapy regimens for patients with advanced gastro-esophageal adenocarcinoma (aGEA) in Europe. To enable outpatient treatment, we evaluated the maximum tolerated dose (MTD), recommended dose (RD), dose limiting toxicity (DLT) and safety of docetaxel in combination with oxaliplatin (O) and S-1 (DOS) in Caucasian patients with aGEA. Methods: We present final results of two parallel phase 1/2a studies (3 + 3 design). Escalating doses of docetaxel and S-1 with fixed dose O were given for 18 weeks every second week (DOS2w) or every third week (DOS3w) followed by S-1 maintenance therapy. Results: Thirty-four patients (18 in DOS2w and 16 in DOS3w) were enrolled between October 2013 and June 2015. Median age was 65 years (range 49–78). DLT was most often febrile neutropenia. Most common severe non-hematological adverse events were diarrhea (9%) and fatigue (6%). The RD of DOS3w was: docetaxel 50 mg/m 2, O 100 mg/m 2 and S-1 25 mg/m 2 twice daily and of DOS2w was: docetaxel 40 mg/m 2, O 70 mg/m 2 and S-1 35 mg/m 2 twice daily. Overall, response rate was 56%; median progression-free survival was 9.1 months; and median overall survival was 13.2 months in 34 patients. Conclusions: At the RD, DOS2w and DOS3w showed an acceptable safety profile in patients with aGEA. Clinical trials ID: NCT-01928524 and EudraCT 2012-005187-10